Jana Markova

TL;DR: Treatment with six cycles of BEACOPP(escalated) followed by PET-guided radiotherapy was more effective in terms of freedom from treatment failure and less toxic than eight cycles of the same chemotherapy regimen, and should be the treatment of choice for advanced stage Hodgkin's lymphoma.

TL;DR: Moderate dose escalation using BEACOPP(baseline) did not significantly improve outcome in early unfavorable HL, and four cycles of ABVD should be followed by 30 Gy of IFRT.

TL;DR: Intensified chemotherapy with two cycles of BEACOPP escalated followed by three cycles of ABVD followed by IFRT significantly improves tumor control in patients with early unfavorable HL.

TL;DR: This open-label, randomised, parallel-group phase 3 trial investigated whether metabolic response determined by PET after two cycles of standard regimen eBEACOPP (PET-2) would allow adaption of treatment intensity, increasing it for PET-2-positive patients and reducing it forPET- 2-negative patients and showed non-inferiority in the 5-year progression-free survival estimates.

TL;DR: Responsible response adapted therapy guided by PET for HL patients seems to be a promising approach that should be further evaluated in clinical trials.